The Cynergy workstation with MultiPlex technology marks an innovative development in the treatment of dermatological vascular conditions through the use of laser based technology.
This system recently received FDA clearance and is the first system to enable the rapid sequential emission of two wavelengths from the same optical fiber -- a pulse-dye laser and a Nd:YAG laser -- with a short time delay between the two pulses. The time delay increases the safety and effectiveness of laser treatment.
"The Cynergy workstation with MultiPlex technology is the culmination of significant research and development efforts not only internally, but collaboratively with leading clinicians at the forefront of their specialty utilizing cutting-edge technology," said Michael R. Davin, CEO of Cynosure, Inc..
"We are proud to offer the first single laser system that will enable doctors to customise treatment options specific to their patients' needs to achieve significantly improved results for a range of vascular applications."
In clinical studies, treatments using the Cynergy workstation with MultiPlex technology have shown an increased depth of penetration of energy and improved effectiveness in treating portwine stains, and improved outcomes for facial and leg telangiectasia when compared to treatments using a pulse- dye laser or a Nd:YAG laser individually.
David Goldberg, M.D., clinical professor of dermatology at Mount Sinai School of Medicine in New York City, states, "When treating portwine stains, hemangiomas and spider veins, it is very clear that you achieve a better overall effect when using these two wavelengths together than with either wavelength separately."
"The use of either a pulse-dye laser or a Nd:YAG laser alone has limits," commented Emil Tanghetti, M.D., clinical professor of cosmetic dermatology at the University of California, Davis. "However, when combined, these two wavelengths appear to be effective for treating many vascular lesions such as blebbed portwine stains and difficult facial telangiectasia, which were resistant to treatment in the past. This is a truly innovative and exciting development."
